EP1908477A3
Combination of temozolomide and pegylated interferon-alpha for treating cancer
Abstract
A method for treating a human patient afflicted with cancer, comprising administering therapeutically effective amounts of temozolomide and pegylated interferon alpha to such a patient.
Term
Term ended
Projected expiry passed 22 January 2021, 5.7 years ago.
- Priority
- Filed
- Published
- Projected expiry
- Today
Every citation, both ways
| Document | Relation | Office | Category | Cited during | Relevant claims |
|---|---|---|---|---|---|
| EP0593868A1 | Cites | European Patent Office (EPO) | Y | Search report | 1-22 |
| EP0809996A2 | Cites | European Patent Office (EPO) | Y | Search report | 1-22 |
| WO9513090A1 | Cites | World Intellectual Property Organization (WIPO) | Y | Search report | 1-22 |
| WO9712630A1 | Cites | World Intellectual Property Organization (WIPO) | Y | Search report | 1-22 |
| WO9948535A1 | Cites | World Intellectual Property Organization (WIPO) | Y | Search report | 1-22 |
10 members in 7 offices
Priority claims7
| Document | Office | Kind | Date |
|---|---|---|---|
| 177624P | United States of America | – | |
| 17762400 | United States of America | P | |
| 01905031 | European Patent Office (EPO) | A | |
| 01905031 | – | – | – |
| 177624P | – | – | – |
| EP20010905031 | – | – | – |
| US20000177624P | – | – | – |
Members10
| Document | Office | Kind | |
|---|---|---|---|
| CA2397793A1 | Canada | A1 | |
| WO0152882A1 | World Intellectual Property Organization (WIPO) | A1 | |
| AU3295101A | Australia | A | |
| US2002009428A1 | United States of America | A1 | |
| EP1251866A1 | European Patent Office (EPO) | A1 | |
| MXPA02007172A | Mexico | A | |
| JP2003520247A | Japan | A | |
| US2004223951A1 | United States of America | A1 | |
| EP1908477A2 | European Patent Office (EPO) | A2 | |
| EP1908477A3This record | European Patent Office (EPO) | A3 |
11 legal events, as 2 offices reported them to INPADOC
Over the term
Point at a mark for the eventEvents
| Event | Code | Office | |
|---|---|---|---|
| Designated country de not longer valid8566 | 8566 | DE | |
| Application deemed to be withdrawnWithdrawn18D | 18D | EP | |
| Information on the status of an ep patent application or granted ep patentGrantedSTATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWNSTAA | STAA | EP | |
| Designation fees paidAKX | AKX | EP | |
| Designated contracting statesAK | AK | EP | |
| Request for extension of the european patentAX | AX | EP | |
| Search report despatchedORIGINAL CODE: 0009013PUAL | PUAL | EP | |
| Divisional application: reference to earlier applicationAC | AC | EP | |
| Designated contracting statesAK | AK | EP | |
| Request for extension of the european patentAX | AX | EP | |
| Public reference made under article 153(3) epc to a published international application that has entered the european phaseORIGINAL CODE: 0009012PUAI | PUAI | EP |
Numbers
- Publication
- 1908477
- Publication, DOCDB
- 1908477
- Publication, EPODOC
- EP1908477
- Application
- 7013531
- Application, DOCDB
- 07013531
- Application, EPODOC
- EP20070013531
Titles3
- German
- Kombination aus Temozolomid und pegyliertem Interferon-alpha zur Krebsbehandlung
- English
- Combination of temozolomide and pegylated interferon-alpha for treating cancer
- French
- Combinaison de témozolomide et interféron alpha pégylé pour le traitement du cancer
Classification
- CPC, 3
- A61K38/212
- A61K38/00
- A61P35/00
- IPC, 5
- A61K38 21
- A61K31 395
- A61K31 53
- A61K38 12
- A61P35 00
Designated states2
- Contracting states, 1
- Türkiye
- Extension states, 1
- Slovenia